This article by contributing author Neil Gray, examines why the industry's current use of tactical value measures for MSLs might ultimately prove limiting by positioning MSLs inappropriately and inhibiting their broader involvement in organizational and stakeholder problem-solving.
The author examines how tomorrow's MSL might be employed by Pharma and discusses the strategic movement of MSLs into the competitive intelligence space, teaching roles, strategic input to and evaluation of portfolio development, and investor relations.
Topics and issues covered include:
Read this article now. It's FREE...
- Difficult Times Lie Ahead
- Numerous Stakeholder Challenges
- What Do KOLs Want?
- Moving From Science Discussants to Knowledge Directors
- What the Future May Hold
Download PDF file